Investors & Media

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

NASDAQ : CUE

$9.28

0(0%)

Volume 0

As of: 09/18/2019 10:42

Investor Kit

Recent News

Learn how Immuno-STAT Biologics selectively modulate disease-associated T cells to fight cancer.
 Play Video